Regulation of Estrogen Receptor α N-Terminus Conformation and Function by Peptidyl Prolyl Isomerase Pin1

REFERENCES

• Acevedo ML, Lee KC, Stender JD, Katzenellenbogen BS, Kraus WL. 2004. Selective recognition of distinct classes of coactivators by a ligand-inducible activation domain. Mol. Cell 13:725–738.
   PubMedGoogle Scholar
• Ali S, Metzger D, Bornert JM, Chambon P. 1993. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J. 12:1153–1160.
   PubMed Web of Science ®Google Scholar
• Atsriku C, et al. 2009. Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites. Mol. Cell. Proteomics 8:467–480.
   PubMed Web of Science ®Google Scholar
• Bartels C, Xia T-H, Billeter M, Güntert P, Wüthrich K. 1995. The program XEASY for computer-supported NMR spectral analysis of biological macromolecules. J. Biomol. NMR 6:1–10.
   PubMed Web of Science ®Google Scholar
• Berry M, Metzger D, Chambon P. 1990. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 9:2811–2818.
   PubMed Web of Science ®Google Scholar
• Bocchinfuso WP, Korach KS. 1997. Estrogen receptor residues required for stereospecific ligand recognition and activation. Mol. Endocrinol. 11:587–594.
   PubMedGoogle Scholar
• Borras M, et al. 1996. Estrogenic and anti-estrogenic regulation of half-life of covalently labeled estrogen receptor in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol. 57:203–216.
   PubMed Web of Science ®Google Scholar
• Britton DJ, et al. 2006. Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res. Treat. 96:131–146.
   PubMed Web of Science ®Google Scholar
• Brondani V, Schefer Q, Hamy F, Klimkait T. 2005. The peptidyl-prolyl isomerase Pin1 regulates phospho-Ser77 retinoic acid receptor alpha stability. Biochem. Biophys. Res. Commun. 328:6–13.
   PubMedGoogle Scholar
• Brzozowski AM, et al. 1997. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753–758.
   PubMed Web of Science ®Google Scholar
• Bunone G, Briand PA, Miksicek RJ, Picard D. 1996. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15:2174–2183.
   PubMed Web of Science ®Google Scholar
• Calligé M, Kieffer I, Richard-Foy H. 2005. CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptorα by the proteasome. Mol. Cell. Biol. 25:4349–4358.
   PubMed Web of Science ®Google Scholar
• Castles CG, Oesterreich S, Hansen R, Fuqua SA. 1997. Auto-regulation of the estrogen receptor promoter. J. Steroid Biochem. Mol. Biol. 62:155–163.
   PubMed Web of Science ®Google Scholar
• Chen D, et al. 2000. Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol. Cell 6:127–137.
   PubMed Web of Science ®Google Scholar
• Cheng J, Zhang C, Shapiro DJ. 2007. A functional serine 118 phosphorylation site in estrogen receptor-alpha is required for down-regulation of gene expression by 17β-estradiol and 4-hydroxytamoxifen. Endocrinology 148:4634–4641.
   PubMed Web of Science ®Google Scholar
• Clarke RB, Howell A, Potten CS, Anderson E. 1997. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 57:4987–4991.
   PubMed Web of Science ®Google Scholar
• Couse JF, Korach KS. 1999. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev. 20:358–417.
   PubMed Web of Science ®Google Scholar
• Delaglio F, et al. 1995. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6:277–293.
   PubMed Web of Science ®Google Scholar
• Dowsett M, et al. 2010. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol. 28:509–518.
   PubMed Web of Science ®Google Scholar
• Duplessis TT, Koterba KL, Rowan BG. 2009. Detection of ERα-SRC-1 interactions using bioluminescent resonance energy transfer. Methods Mol. Biol. 590:253–263.
   PubMedGoogle Scholar
• Duplessis TT, Williams CC, Hill SM, Rowan BG. 2011. Phosphorylation of estrogen receptor alpha at serine 118 directs recruitment of promoter complexes and gene-specific transcription. Endocrinology 152:2517–2526.
   PubMed Web of Science ®Google Scholar
• Dyson HJ, Wright PE. 2005. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 6:197–208.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. 2005. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717.
   PubMed Web of Science ®Google Scholar
• Einarson MB, Pugacheva EN, Orlinick JR. 2007. Far Western: probing membranes. Cold Spring Harb. Protoc. 2007. https://doi.org/10.1101/pdb.prot4759.
   Google Scholar
• Ellison-Zelski SJ, Solodin NM, Alarid ET. 2009. Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter. Mol. Cell. Biol. 29:4949–4958.
   PubMed Web of Science ®Google Scholar
• Endoh H, et al. 1999. Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha. Mol. Cell. Biol. 19:5363–5372.
   PubMed Web of Science ®Google Scholar
• Fabris G, et al. 1987. Pathophysiology of estrogen receptors in mammary tissue by monoclonal antibodies. J. Steroid Biochem. 27:171–176.
   PubMedGoogle Scholar
• Faus H, Haendler B. 2006. Post-translational modifications of steroid receptors. Biomed. Pharmacother. 60:520–528.
   PubMed Web of Science ®Google Scholar
• Fila C, Metz C, van der Sluijs P. 2008. Juglone inactivates cysteine-rich proteins required for progression through mitosis. J. Biol. Chem. 283:21714–21724.
   PubMedGoogle Scholar
• Fowler AM, et al. 2004. Increases in estrogen receptor-alpha concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen. FASEB J. 18:81–93.
   PubMedGoogle Scholar
• Fujimoto Y, et al. 2010. Proline cis/trans-isomerase Pin1 regulates peroxisome proliferator-activated receptor gamma activity through the direct binding to the activation function-1 domain. J. Biol. Chem. 285:3126–3132.
   PubMedGoogle Scholar
• Gburcik V, Bot N, Maggiolini M, Picard D. 2005. SPBP is a phosphoserine-specific repressor of estrogen receptor alpha. Mol. Cell. Biol. 25:3421–3430.
   PubMedGoogle Scholar
• Gburcik V, Picard D. 2006. The cell-specific activity of the estrogen receptor alpha may be fine-tuned by phosphorylation-induced structural gymnastics. Nucl. Recept. Signal. 4:e005.
   PubMedGoogle Scholar
• Gutierrez MC, et al. 2005. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 23:2469–2476.
   PubMed Web of Science ®Google Scholar
• Heldring N, et al. 2007. Structural insights into corepressor recognition by antagonist-bound estrogen receptors. J. Biol. Chem. 282:10449–10455.
   PubMed Web of Science ®Google Scholar
• Hennig L, et al. 1998. Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone. Biochemistry 37:5953–5960.
   PubMed Web of Science ®Google Scholar
• Henrich LM, et al. 2003. Extracellular signal-regulated kinase 7, a regulator of hormone-dependent estrogen receptor destruction. Mol. Cell. Biol. 23:5979–5988.
   PubMedGoogle Scholar
• Ince BA, Zhuang Y, Wrenn CK, Shapiro DJ, Katzenellenbogen BS. 1993. Powerful dominant negative mutants of the human estrogen receptor. J. Biol. Chem. 268:14026–14032.
   PubMedGoogle Scholar
• Jenster G, et al. 1997. Steroid receptor induction of gene transcription: a two-step model. Proc. Natl. Acad. Sci. U. S. A. 94:7879–7884.
   PubMedGoogle Scholar
• Jiang SY, Wolf DM, Yingling JM, Chang C, Jordan VC. 1992. An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol. Cell. Endocrinol. 90:77–86.
   PubMedGoogle Scholar
• Kariagina A, Aupperlee MD, Haslam SZ. 2007. Progesterone receptor isoforms and proliferation in the rat mammary gland during development. Endocrinology 148:2723–2736.
   PubMed Web of Science ®Google Scholar
• Kariagina A, Xie J, Leipprandt JR, Halsam SZ. 2010. Amphiregulin mediates estrogen, progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers. Hormones Cancer 1:229–244.
   PubMedGoogle Scholar
• Kato S, et al. 1995. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491–1494.
   PubMed Web of Science ®Google Scholar
• Kay L, Keifer P, Saarinen T. 1992. Pure absorption gradient enhanced heteronuclear single quantum correlation spectroscopy with improved sensitivity. J. Am. Chem. Soc. 114:10663–10665.
   Web of Science ®Google Scholar
• Knowlden JM, et al. 2003. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144:1032–1044.
   PubMed Web of Science ®Google Scholar
• Koterba KL, Rowan BG. 2006. Measuring ligand-dependent and ligand-independent interactions between nuclear receptors and associated proteins using bioluminescence resonance energy transfer (BRET). Nucl. Recept. Signal. 4:e021.
   PubMedGoogle Scholar
• Kumar V, Chambon P. 1988. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55:145–156.
   PubMed Web of Science ®Google Scholar
• Lannigan DA. 2003. Estrogen receptor phosphorylation. Steroids 68:1–9.
   PubMed Web of Science ®Google Scholar
• Lavery DN, McEwan IJ. 2005. Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations. Biochem. J. 391:449–464.
   PubMed Web of Science ®Google Scholar
• Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS. 1994. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J. Biol. Chem. 269:4458–4466.
   PubMed Web of Science ®Google Scholar
• Lees JA, Fawell SE, White R, Parker MG. 1990. A 22-amino-acid peptide restores DNA-binding activity to dimerization-defective mutants of the estrogen receptor. Mol. Cell. Biol. 10:5529–5531.
   PubMedGoogle Scholar
• Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA. 2006. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol. Endocrinol. 20:3120–3132.
   PubMedGoogle Scholar
• Lim J, et al. 2008. Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J. Clin. Invest. 118:1877–1889.
   PubMedGoogle Scholar
• Lu KP, Finn G, Lee TH, Nicholson LK. 2007. Prolyl cis-trans isomerization as a molecular timer. Nat. Chem. Biol. 3:619–629.
   PubMed Web of Science ®Google Scholar
• Lu KP, Hanes SD, Hunter T. 1996. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 380:544–547.
   PubMed Web of Science ®Google Scholar
• Lu KP, Liou YC, Zhou XZ. 2002. Pinning down proline-directed phosphorylation signaling. Trends Cell Biol. 12:164–172.
   PubMed Web of Science ®Google Scholar
• Lu KP, Zhou XZ. 2007. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat. Rev. Mol. Cell Biol. 8:904–916.
   PubMed Web of Science ®Google Scholar
• Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. 1999. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399:784–788.
   PubMed Web of Science ®Google Scholar
• Lykkesfeldt AE, Madsen MW, Briand P. 1994. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res. 54:1587–1595.
   PubMed Web of Science ®Google Scholar
• Mantovani F, et al. 2004. Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol. Cell 14:625–636.
   PubMedGoogle Scholar
• Markley JL, et al. 2009. The Center for Eukaryotic Structural Genomics J. Struct. Funct. Genomics 10:165–179.
   PubMedGoogle Scholar
• Marsaud V, Gougelet A, Maillard S, Renoir J-M. 2003. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor α (ERα) differentially affect ERα extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol. Endocrinol. 17:2013–2027.
   PubMed Web of Science ®Google Scholar
• Masuhiro Y, et al. 2005. Splicing potentiation by growth factor signals via estrogen receptor phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 102:8126–8131.
   PubMedGoogle Scholar
• McInerney EM, Katzenellenbogen BS. 1996. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation. J. Biol. Chem. 271:24172–24178.
   PubMedGoogle Scholar
• McKenna NJ, Lanz RB, O'Malley BW. 1999. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 20:321–344.
   PubMed Web of Science ®Google Scholar
• Medunjanin S, et al. 2005. Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor alpha and is involved in the regulation of receptor activity. J. Biol. Chem. 280:33006–33014.
   PubMed Web of Science ®Google Scholar
• Murphy LC, Seekallu SV, Watson PH. 2011. Clinical significance of estrogen receptor phosphorylation. Endocr. Relat. Cancer 18:R1–R14.
   PubMed Web of Science ®Google Scholar
• Namgoong GM, et al. 2010. The prolyl-isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer. J. Biol. Chem. 285:23829–23841.
   PubMedGoogle Scholar
• Pakdel F, Reese JC, Katzenellenbogen BS. 1993. Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor. Mol. Endocrinol. 7:1408–1417.
   PubMedGoogle Scholar
• Pons M, Gagne D, Nicolas JC, Mehtali M. 1990. A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules. Biotechniques 9:450–459.
   PubMed Web of Science ®Google Scholar
• Powell E, Xu W. 2008. Intermolecular interactions identify ligand-selective activity of estrogen receptor alpha/beta dimers. Proc. Natl. Acad. Sci. U. S. A. 105:19012–19017.
   PubMedGoogle Scholar
• Powers GL, Ellison-Zelski SJ, Casa AJ, Lee AV, Alarid ET. 2010. Proteasome inhibition represses ERα gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer. Oncogene 29:1509–1518.
   PubMed Web of Science ®Google Scholar
• Ramelot TA, Nicholson LK. 2001. Phosphorylation-induced structural changes in the amyloid precursor protein cytoplasmic tail detected by NMR. J. Mol. Biol. 307:871–884.
   PubMedGoogle Scholar
• Ranganathan R, Lu KP, Hunter T, Noel JP. 1997. Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell 89:875–886.
   PubMed Web of Science ®Google Scholar
• Ring A, Dowsett M. 2004. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 11:643–658.
   PubMed Web of Science ®Google Scholar
• Rochette-Egly C. 2003. Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell. Signal. 15:355–366.
   PubMed Web of Science ®Google Scholar
• Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP. 2001. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat. Cell Biol. 3:793–801.
   PubMed Web of Science ®Google Scholar
• Ryo A, et al. 2003. Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol. Cell 12:1413–1426.
   PubMed Web of Science ®Google Scholar
• Sarkar P, Reichman C, Saleh T, Birge RB, Kalodimos CG. 2007. Proline cis-trans isomerization controls autoinhibition of a signaling protein. Mol. Cell 25:413–426.
   PubMed Web of Science ®Google Scholar
• Sarkar P, Saleh T, Tzeng SR, Birge RB, Kalodimos CG. 2011. Structural basis for regulation of the Crk signaling protein by a proline switch. Nat. Chem. Biol. 7:51–57.
   PubMed Web of Science ®Google Scholar
• Sarwar N, et al. 2006. Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression. Endocr. Relat. Cancer 13:851–861.
   PubMed Web of Science ®Google Scholar
• Schutkowski M, et al. 1998. Role of phosphorylation in determining the backbone dynamics of the serine/threonine-proline motif and Pin1 substrate recognition. Biochemistry 37:5566–5575.
   PubMedGoogle Scholar
• Schwabe JW, Chapman L, Finch JT, Rhodes D. 1993. The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell 75:567–578.
   PubMed Web of Science ®Google Scholar
• Shaaban AM, Sloane JP, West CR, Foster CS. 2002. Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am. J. Pathol. 160:597–604.
   PubMed Web of Science ®Google Scholar
• Shiau AK, et al. 1998. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927–937.
   PubMed Web of Science ®Google Scholar
• Stanya KJ, Liu Y, Means AR, Kao HY. 2008. Cdk2 and Pin1 negatively regulate the transcriptional corepressor SMRT. J. Cell Biol. 183:49–61.
   PubMedGoogle Scholar
• Suizu F, Ryo A, Wulf G, Lim J, Lu KP. 2006. Pin1 regulates centrosome duplication, and its overexpression induces centrosome amplification, chromosome instability, and oncogenesis. Mol. Cell. Biol. 26:1463–1479.
   PubMedGoogle Scholar
• Tamrazi A, Carlson KE, Daniels JR, Hurth KM, Katzenellenbogen JA. 2002. Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate. Mol. Endocrinol. 16:2706–2719.
   PubMed Web of Science ®Google Scholar
• Tan X, et al. 2010. Pin1 expression contributes to lung cancer: prognosis and carcinogenesis. Cancer Biol. Ther. 9:111–119.
   PubMed Web of Science ®Google Scholar
• Tora L, et al. 1989. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59:477–487.
   PubMed Web of Science ®Google Scholar
• Valley CC, et al. 2005. Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus. Mol. Cell. Biol. 25:5417–5428.
   PubMed Web of Science ®Google Scholar
• Warnmark A, Wikstrom A, Wright AP, Gustafsson JA, Hard T. 2001. The N-terminal regions of estrogen receptor alpha and beta are unstructured in vitro and show different TBP binding properties. J. Biol. Chem. 276:45939–45944.
   PubMedGoogle Scholar
• Watanabe M, et al. 2001. A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor alpha coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA. EMBO J. 20:1341–1352.
   PubMedGoogle Scholar
• Watters JJ, Campbell JS, Cunningham MJ, Krebs EG, Dorsa DM. 1997. Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 138:4030–4033.
   PubMed Web of Science ®Google Scholar
• Weigel NL, Moore NL. 2007. Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol. Endocrinol. 21:2311–2319.
   PubMed Web of Science ®Google Scholar
• Weigel NL, Zhang Y. 1998. Ligand-independent activation of steroid hormone receptors. J. Mol. Med. 76:469–479.
   PubMedGoogle Scholar
• Werner-Allen JW, et al. 2011. cis-Proline-mediated Ser(P)5 dephosphorylation by the RNA polymerase II C-terminal domain phosphatase Ssu72. J. Biol. Chem. 286:5717–5726.
   PubMed Web of Science ®Google Scholar
• Wulf G, Finn G, Suizu F, Lu KP. 2005. Phosphorylation-specific prolyl isomerization: is there an underlying theme? Nat. Cell Biol. 7:435–441.
   PubMed Web of Science ®Google Scholar
• Wulf GM, Liou YC, Ryo A, Lee SW, Lu KP. 2002. Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J. Biol. Chem. 277:47976–47979.
   PubMed Web of Science ®Google Scholar
• Wulf GM, et al. 2001. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 20:3459–3472.
   PubMed Web of Science ®Google Scholar
• Yaffe MB, et al. 1997. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 278:1957–1960.
   PubMed Web of Science ®Google Scholar
• Yi P, et al. 2005. Peptidyl-prolyl isomerase 1 (Pin1) serves as a coactivator of steroid receptor by regulating the activity of phosphorylated steroid receptor coactivator 3 (SRC-3/AIB1). Mol. Cell. Biol. 25:9687–9699.
   PubMedGoogle Scholar
• Zhang J, Socolovsky M, Gross AW, Lodish HF. 2003. Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry-based novel culture system. Blood 102:3938–3946.
   PubMed Web of Science ®Google Scholar
• Zheng H, et al. 2002. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 419:849–853.
   PubMed Web of Science ®Google Scholar
• Zhou XZ, et al. 2000. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol. Cell 6:873–883.
   PubMed Web of Science ®Google Scholar